Compare ARK Fintech Innovation ETF (ARKF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Zimmer Biomet Holdings Inc — how do they compare? ARK Fintech Innovation ETF trades at $42.85, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while ARK Fintech Innovation ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $107.71 |
52-Week Low | $36.14 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.82, down 0.65% on the day, with technical indicators showing mixed signals. The ETF maintains a bullish moving average trend but faces neutral oscillator readings. Recent performance has been challenging, with the fund down 23% since July 2025 and underperforming the S&P 500 by 45 percentage points. Portfolio volatility remains elevated at 33.6%, reflecting the high-risk nature of fintech and blockchain innovation investments.
The outlook remains cautious with fair valuation concerns and ongoing technical consolidation. Investment opportunity exists in the long-term fintech growth theme, but risks include high volatility, elevated P/E ratio of 33x, and competitive pressures. Current sentiment suggests a hold rating as the fund navigates market challenges.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
